<table id="_Reftb13" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 13 Established and Other Potentially Significant Drug Interactions</caption>
<col width="35%"></col>
<col width="26%"></col>
<col width="39%"></col>
<thead>
<tr>
<th align="left" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<content stylecode="bold">Concomitant Drug</content>
<br/>
</th>
<th align="left" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<content stylecode="bold">Effect on Concentration of Lamotrigine or Concomitant Drug</content>
</th>
<th align="left" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<content stylecode="bold">Clinical Comment</content>
<br/>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3" stylecode="Botrule" valign="top">↓ = Decreased (induces lamotrigine glucuronidation)<br/>↑ =  Increased (inhibits lamotrigine glucuronidation)<br/>? = Conflicting data</td>
</tr>
</tfoot>
<tbody>
<tr>
<td rowspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Estrogen-containing oral contraceptive preparations containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>↓ lamotrigine<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Decrease in levonorgestrel component by 19%</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓ levonorgestrel<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Decrease in levonorgestrel component by 19%<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule " valign="top">
<paragraph>Carbamazepine (CBZ) and CBZ epoxide<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓ lamotrigine<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Addition of carbamazepine decreases lamotrigine concentration approximately 40%<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="middle"></td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>? CBZ epoxide<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>May increase CBZ epoxide levels.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Phenobarbital/Primidone<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓ lamotrigine<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Decreased lamotrigine concentration approximately 40%<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Phenytoin (PHT)<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓ lamotrigine<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Decreased lamotrigine concentration approximately 40%<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Rifampin<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↓ lamotrigine<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Decreased lamotrigine AUC approximately 40%<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Valproate<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>↑ lamotrigine<br/>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Increased lamotrigine concentrations slightly more than 2-fold<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top"></td>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>? valproate<br/>
</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Decreased valproate concentrations an average of 25% over a 3-week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients.<br/>
</paragraph>
</td>
</tr>
</tbody>
</table>